Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Medicine
Published in: Clinical and Experimental Medicine 2/2011

Open Access 01-06-2011 | Original Article

Glycosylation of mucins present in gastric juice: the effect of helicobacter pylori eradication treatment

Authors: Iwona Radziejewska, Małgorzata Borzym-Kluczyk, Zbigniew Namiot, Ewa Stefańska

Published in: Clinical and Experimental Medicine | Issue 2/2011

Login to get access

Abstract

It is suggested that gastric mucins, and in particular some specific glycan structures that can act as carbohydrate receptors, are involved in the interactions with Helicobacter pylori adhesins. The main aim of our study was to evaluate glycosylation pattern of glycoproteins of gastric juice before and at the end of eradication therapy. Gastric juices were taken from 13 clinical patients and subjected to analysis. Pooled fractions of the void volume obtained after gel filtration were subjected to ELISA tests. To assess the relative amounts of carbohydrate structures, lectins and monoclonal antibodies were used. Changes in the level of MUC 1 and MUC 5AC mucins and of carbohydrate structures, which are suggested to be receptors for Helicobacter pylori adhesins, were observed by the end of the eradication treatment. Our results support the idea about the involvement of MUC 5AC and MUC 1 with some specific sugar structures in the mechanism of Helicobacter pylori infection.
Literature
1.
Corfield AP, Myerscough N, Longman R, Sylvester P, Arul S, Pignatelli M (2000) Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. Gut 47:589–594PubMedCrossRef
2.
Uemura N, Okamoto S, Yamamoto S et al (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 11:784–789CrossRef
3.
Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA (2008) Mucins in the mucosal barrier to infection. Mucosal Immunol 1:183–197PubMedCrossRef
4.
Nordman H, Davies JR, Lindell G, de Bolos C, Real F, Carlstedt I (2002) Gastric MUC 5AC and MUC 6 are large oligomeric mucins that differ in size, glycosylation and tissue distribution. Biochem J 364:191–200PubMed
5.
6.
Orczyk-Pawiłowicz M, Floriański J, Zalewski J, Kątnik-Prastowska I (2005) Relative amounts of sialic acid and fucose of amniotic fluid glycoconjugates in relation to pregnancy age. Glycoconjugate J 22:433–442CrossRef
7.
Linden S, Mahdavi J, Hedenbro J, Boren T, Carlstedt I (2004) Effects of pH on Helicobacter pylori binding to human gastric mucins; identification of binding to non-MUC 5AC mucins. Biochem J 384:263–270PubMedCrossRef
8.
Bovenkamp JHB, Mahdavi J, Korteland-Van Male AM et al (2003) The MUC 5AC glycoprotein is the primary receptor for Helicobacter pylori in the human stomach. Helicobacter 8:521–532PubMedCrossRef
9.
Linden S, Nordman H, Hedenbro J, Hurtig M, Boren T, Carlstedt I (2002) Strain- and blood group—dependent binding of Helicobacter pylori to human gastric MUC 5AC glycoforms. Gastroenterology 123:1923–1930PubMedCrossRef
10.
Mahdavi J, Sonden B, Hurtig M et al (2002) Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 297:573–578PubMedCrossRef
11.
Ilver D, Arnaqvist A, Őrgen J et al (1998) Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 279:373–377PubMedCrossRef
12.
Sheu BS, Odenbreit S, Hung KH et al (2006) Interaction between host gastric sialyl-Lewis x and H. pylori SabA enhances H. pylori density in patients lacking gastric Lewis b antigen. Am J Gastroenterol 101:36–44PubMedCrossRef
13.
McGuckin MA, Every AL, Skene CD, Linden SK et al (2007) Muc 1 mucin limits both Helicobacter pylori colonization of the murine gastric mucosa and associated gastritis. Gastroenterology 133:1210–1218PubMedCrossRef
14.
Ota H, Nakayama J, Momose M et al (1998) Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virchows Arch 433:419–426PubMedCrossRef
15.
Radziejewska I, Borzym-Kluczyk M, Kisiel DG, Namiot Z, Wosek J, Gindzieński A (2008) The effect of Helicobacter pylori eradication tratment on the MUC 1 and Lewis antigens level in human gastric juice: a preliminary study. Dig Dis Sci 53:2641–2645PubMedCrossRef
16.
Smith PK, Krohn RJ, Hermanson GT (1985) Measurement of protein using bicinchoninic acid. Anal Chem 150:76–85
17.
Hanisch FG, Muller S (2000) MUC 1: the polymorphic appearance of human mucin. Glycobiology 10:439–449PubMedCrossRef
18.
Cooke CL, An HJ, Kim J et al (2009) Modification of gastric mucin oligosaccharide expression in rhesus macaques after infection with Helicobacter pylori. Gastroenterology 137:1061–1071PubMedCrossRef
19.
Byrd JC, Yunker CK, Xu Q-S, Sternberg LR, Bresalier RS (2000) Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology 118:1072–1079PubMedCrossRef
20.
Kocer B, Ulas M, Ustundag Y et al (2004) A confirmatory report for the close interaction of Helicobacter pylori with gastric epithelial MUC 5AC expression. J Clin Gastroenterol 38:496–502PubMedCrossRef
21.
Radziejewska I, Kisiel DG, Borzym-Kluczyk M, Kluz A, Namiot Z, Gindzieński A (2007) MUC 1 mucin kontent in gastric juice of duodenal ulcer patients: effect of Helicobacter pylori eradication therapy. Clin Exp Med 7:72–76PubMedCrossRef
22.
Linden S, Wickstrom C, Lindell G, K Gilshenan, Carlstedt I (2008) Four models of adhesion are used during Helicobacter pylori binding to human mucins in the oral and gastric niches. Helicobacter 13:81–93PubMedCrossRef
23.
Linden S, Sheng Y, Every A et al (2009) MUC 1 limits Helicobacter pylori infection both by steric hindrance and by acting as releasable decoy. PLoS Pathog 5:e1000617PubMedCrossRef
24.
Radziejewska I, Gindzieński A, Wosek J, Kożuszyńska-Topór M, Namiot Z (2004) The influence of omeprazole treatment on MUC 1 mucin contents in gastric juice of Helicobacter pylori infected patients. Gastroenterol Pol 11:435–438
25.
Yamashita K, Kochibe N, Ohkura T, Ueda I, Kobata A (1985) Fractionation of L-fucose-containing oligosaccharides on immobilized Aleuria auranta lectin. J Biol Chem 260:4688–4693PubMed
26.
Audette GF, Vandonselaar M, Delbaere LTJ (2000) The 2.2 Å resolution structure of the O(H) blood-group-specific Lectin I from Ulex europaeus. J Mol Biol 304:423–433PubMedCrossRef
27.
Yan L, Wilkins PP, Alvarez-Manilla G, Do SI, Smith DF, Cummings RD (1997) Immobilized Lotus tetragonolobus agglutinin binds oligosaccharides containing the Lex determinant. Glycoconjugate J 14:45–55CrossRef
28.
Wang WC, Cummings RD (1988) The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2, 3 to penultimate galactose residues. J Biol Chem 263:4576–4585PubMed
29.
Shibuya N, Goldstein IJ, Broekaert WF, Nsimba-Lubaki M, Peeters B, Peumans WJ (1987) The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac (alpha 2–6) Gal/GalNAc sequence. J Biol Chem 262:1596–1601PubMed
30.
Sharma V, Vijayan M, Surolia A (1996) Imparting equisite specificity to peanut agglutinin for the tumor-associated Thomsen-Friedenreich antigen by redesign of its combining site. J Biol Chem 271:1209–21213CrossRef
31.
Wu AM (2004) Polyvalency of Tn (GalNAcα → Ser/Thr) glycotope as a critical factor for Vicia villosa B4 and glycoprotein interactions. FEBS Lett 562:51–58PubMedCrossRef
32.
Taketa K, Ichikawa E, Yamamoto T et al (1990) Datura stramonium agglutinin-reactive alpha-fetoprotein isoforms in hepatocellular carcinoma and other tumors. Tumour Biol 11:220–228PubMedCrossRef
33.
Lopez S, Codina C, Bastida J, Viladomat F, Davidson E, Stewart D (2002) Biodiversity of mannose-specific lectins within Narcissus species. J Agric Food Chem 50:2507–2513PubMedCrossRef
34.
Pusztai A, Grant G, Spencer RJ et al (1993) Kidney bean lectin-induced Escherichia coli overgrowth in the small intestine is blocked by GNA, a mannose-specific lectin. J Appl Bacteriol 75:360–368PubMed
Metadata
Title
Glycosylation of mucins present in gastric juice: the effect of helicobacter pylori eradication treatment
Authors
Iwona Radziejewska
Małgorzata Borzym-Kluczyk
Zbigniew Namiot
Ewa Stefańska
Publication date
01-06-2011
Publisher
Springer Milan
Published in
Clinical and Experimental Medicine / Issue 2/2011
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-010-0113-6

Other articles of this Issue 2/2011

Clinical and Experimental Medicine 2/2011 Go to the issue

Original Article

Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer

Original Article

Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population

Short Communication

Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP

Original Article

Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations

Original Article

High mobility group box 1 induces synoviocyte proliferation in rheumatoid arthritis by activating the signal transducer and activator transcription signal pathway

Original Article

DNA amplification on chromosome 13q31.1 correlated with poor prognosis in colorectal cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits